73 related articles for article (PubMed ID: 1479692)
1. [Rapid disappearance of M-protein in multiple myeloma complicated by pneumonia during treatment with HLBI].
Ashihara E; Oku N; Nishio A; Tuji K; Nakamura M
Rinsho Ketsueki; 1992 Dec; 33(12):1818-23. PubMed ID: 1479692
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy of M2-protocol and interferon-alpha as remission induction in refractory multiple myeloma.
Shimamoto Y; Matsuzaki M; Ono K; Sano M; Yamaguchi M
Haematologia (Budap); 1991; 24(1):9-11. PubMed ID: 1813363
[TBL] [Abstract][Full Text] [Related]
3. [New protocols for myeloma chemotherapy plus IFN alpha].
Kitani T
Rinsho Ketsueki; 1993 Apr; 34(4):455-9. PubMed ID: 8510333
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of multiple myeloma with LAK cells plus interleukin 2 or interleukin 2 alone].
Togawa A; Sawada S; Amano M; Oshimi K; Satoh H; Takaku H
Rinsho Ketsueki; 1989 May; 30(5):650-8. PubMed ID: 2795879
[TBL] [Abstract][Full Text] [Related]
5. [Complete remission in multiple myeloma with natural interferon-alpha (HLBI) and melphalan/prednisolone intermittent therapy].
Ito M; Nakagawa T; Imoto S; Isobe T; Nakao Y
Rinsho Ketsueki; 1990 Jun; 31(6):847-52. PubMed ID: 2214176
[TBL] [Abstract][Full Text] [Related]
6. [Clinical trial of a combination of human lymphoblastoid interferon (HLBI) and methyl-prednisolone (HLBI-mP) in multiple myeloma].
Fukuzawa Y; Kawamura T; Ohno R
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3581-6. PubMed ID: 2817909
[TBL] [Abstract][Full Text] [Related]
7. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
[TBL] [Abstract][Full Text] [Related]
8. [Clinical effect of human lymphoblastoid interferon in patients with multiple myeloma].
Yoshida M; Ohta M; Muroi K; Takeda K; Kitagawa S; Tsuboyama A; Sakamoto S; Miura Y; Mutoh Y
Gan To Kagaku Ryoho; 1984 Jul; 11(7):1394-8. PubMed ID: 6742866
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma.
Byrne JL; Carter GI; Bienz N; Haynes AP; Russell NH
Bone Marrow Transplant; 1998 Oct; 22(7):639-43. PubMed ID: 9818690
[TBL] [Abstract][Full Text] [Related]
10. [The successful use of natural alpha-interferon single therapy in multiple myeloma of IgD (lambda)-type].
Suzuki A; Iwase O; Ohkubo T; Nakano M; Toyama K
Rinsho Ketsueki; 1991 Jan; 32(1):47-51. PubMed ID: 1902271
[TBL] [Abstract][Full Text] [Related]
11. Effects of alpha-interferon on MHC unrestricted cytotoxicity in chronic myelogenous leukemia.
Meseri-Delwail A; Delwail V; Brizard A; Goube de Laforest P; Guilhot F; Lecron JC
Biotechnol Ther; 1994; 5(1-2):47-57. PubMed ID: 7703832
[TBL] [Abstract][Full Text] [Related]
12. [Clinical trial of alpha-interferon (human lymphoblastoid interferon) in combination with VCAP chemotherapy in multiple myeloma].
Umeda M; Shirai T; Tsukahara T; Kaneko H; Yamauchi M; Arai N; Kosuge T; Kato M; Shikoshi K; Anno S
Rinsho Ketsueki; 1991 Jun; 32(6):669-74. PubMed ID: 1890744
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.
Abe Y; Muto M; Nieda M; Nakagawa Y; Nicol A; Kaneko T; Goto S; Yokokawa K; Suzuki K
Exp Hematol; 2009 Aug; 37(8):956-68. PubMed ID: 19409955
[TBL] [Abstract][Full Text] [Related]
14. [Clinical trial of a combination of human lymphoblastoid interferon (HLBI), melphalan and prednisolone (HLBI-MP) in multiple myeloma].
Hara M; Nakamura T; Fujii Y
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1338-41. PubMed ID: 3579331
[TBL] [Abstract][Full Text] [Related]
15. Serum beta-2-microglobulin in patients with multiple myeloma treated with alpha interferon.
Murakami H; Ogawara H; Morita K; Saitoh T; Matsushima T; Tamura J; Sawamura M; Karasawa M; Miyawaki S; Schimano S; Satoh S; Tsuchiya J
J Med; 1997; 28(5-6):311-8. PubMed ID: 9604789
[TBL] [Abstract][Full Text] [Related]
16. All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma.
Musto P; Sajeva MR; Sanpaolo G; D'Arena G; Scalzulli PR; Carotenuto M
Haematologica; 1997; 82(3):354-6. PubMed ID: 9234591
[TBL] [Abstract][Full Text] [Related]
17. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
18. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
19. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
